Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™Business Wire • 11/22/24
Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain AlternativeBusiness Wire • 11/21/24
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public OfferingGlobeNewsWire • 11/18/24
Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded WarrantsBusiness Wire • 11/15/24
Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded WarrantsBusiness Wire • 11/13/24
This FactSet Research Analyst Turns Bearish; Here Are Top 4 Downgrades For WednesdayBenzinga • 10/09/24
Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent DevelopmentsBusiness Wire • 08/13/24
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15Business Wire • 08/08/24
Pain Management-Focused Penny Stock Virpax Pharmaceuticals Surges Over 100% On Wednesday-Here's Why?Benzinga • 07/10/24
Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional FundingBusiness Wire • 07/08/24
Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent DevelopmentsBusiness Wire • 05/13/24
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid PriceBusiness Wire • 02/27/24
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.Business Wire • 02/27/24
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical ResearchBusiness Wire • 02/07/24